Predictive Oncology (POAI)
(Delayed Data from NSDQ)
$1.01 USD
+0.02 (2.31%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.99 -0.02 (-1.98%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
POAI 1.01 +0.02(2.31%)
Will POAI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for POAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for POAI
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
POAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
American Well Corporation (AMWL) Reports Q3 Loss, Misses Revenue Estimates
Other News for POAI
Is POAI compressing before expansion? NR7 shows up after advancing 2.31%
POAI forms Upper Bollinger Band Walk on September 18
POAI forms 200 Day Moving Average Resistance on September 17
20 Day Moving Average Support appears for POAI after 9.32% move
Is POAI building bullish momentum? 20 Day Moving Average Support shows up after sinking 1.79%